{
    "clinical_study": {
        "@rank": "149934", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of gefitinib in treating patients who have\n      recurrent and/or metastatic head and neck cancer. Biological therapies such as gefitinib may\n      interfere with the growth of tumor cells by blocking an enzyme necessary for cell growth."
        }, 
        "brief_title": "Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer", 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the disease control rate, in terms of complete response, partial response, and\n      stable disease for at least 4 months, in patients with recurrent and/or metastatic squamous\n      cell cancer of the head and neck treated with gefitinib.\n\n      II. Determine the effect of this drug on epidermal growth factor receptor phosphorylation\n      and expression of selected genes in these patients.\n\n      III. Determine the toxic effects of this drug in these patients.\n\n      OUTLINE: Patients are stratified as delineated in the Disease Characteristics.\n\n      Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of\n      disease progression or unacceptable toxicity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed primary squamous cell cancer of the head\n             and neck that is incurable by surgery or radiotherapy\n\n               -  Stratum I:\n\n                    -  Failed surgery and/or radiotherapy and received no prior systemic\n                       chemotherapy for recurrent disease OR\n\n                    -  Recurrent disease at least 6 months after prior multimodal primary therapy\n                       including neoadjuvant or concurrent chemotherapy OR\n\n                    -  Metastatic disease at initial diagnosis and received no prior chemotherapy\n\n               -  Stratum II:\n\n                    -  No more than 1 prior chemotherapy regimen for recurrent disease OR\n\n                    -  Recurrent disease within 6 months after prior primary therapy that included\n                       chemotherapy\n\n          -  Measurable disease\n\n               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n\n               -  Clear clinical evidence of progression or biopsy-proven residual cancer required\n                  if only site of measurable disease is in a previously irradiated field\n\n          -  No known brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal (no greater than 1.5 times upper limit of normal [ULN] if liver\n             metastases present)\n\n          -  AST/ALT no greater than 2.5 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Other:\n\n          -  No other malignancy within the past 5 years except curatively treated basal cell or\n             squamous cell skin cancer or carcinoma in situ of the cervix\n\n          -  No other uncontrolled concurrent illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study compliance\n\n          -  No prior allergic reactions attributed to compounds of similar chemical or biologic\n             composition to gefitinib\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior therapy with agents that target epidermal growth factor receptors\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and\n             recovered\n\n        Endocrine therapy:\n\n          -  No concurrent tamoxifen\n\n        Radiotherapy:\n\n          -  Prior radiotherapy as primary or secondary treatment allowed\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  Prior surgery as primary or secondary treatment allowed\n\n          -  At least 4 weeks since prior major surgery\n\n        Other:\n\n          -  No other concurrent investigational agents\n\n          -  No concurrent combination antiretroviral therapy for HIV\n\n          -  No concurrent 3A4 inhibitors (e.g., ketoconazole, erythromycin, verapamil)\n\n          -  No concurrent drugs with known corneal toxicity (e.g., chlorpromazine, amiodarone,\n             chloroquine)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00024089", 
            "org_study_id": "CDR0000068890", 
            "secondary_id": [
                "UUMC-8429-01", 
                "NCI-1701"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arm I", 
            "intervention_name": "gefitinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent metastatic squamous neck cancer with occult primary", 
            "metastatic squamous neck cancer with occult primary squamous cell carcinoma", 
            "stage IV squamous cell carcinoma of the lip and oral cavity", 
            "recurrent squamous cell carcinoma of the lip and oral cavity", 
            "stage IV squamous cell carcinoma of the oropharynx", 
            "recurrent squamous cell carcinoma of the oropharynx", 
            "stage IV squamous cell carcinoma of the nasopharynx", 
            "recurrent squamous cell carcinoma of the nasopharynx", 
            "stage IV squamous cell carcinoma of the hypopharynx", 
            "recurrent squamous cell carcinoma of the hypopharynx", 
            "stage IV squamous cell carcinoma of the larynx", 
            "recurrent squamous cell carcinoma of the larynx", 
            "stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity", 
            "recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity", 
            "salivary gland squamous cell carcinoma"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UUMC-8429-01"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84112"
                }, 
                "name": "Huntsman Cancer Institute at University of Utah"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of ZD 1839 (Iressa) in Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck", 
        "overall_official": {
            "affiliation": "University of Utah", 
            "last_name": "Richard H. Wheeler, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Disease control rate", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00024089"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Biologic parameters", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Toxicity", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Response", 
                "safety_issue": "No"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "July 2001", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2005"
    }, 
    "geocoordinates": {
        "Huntsman Cancer Institute at University of Utah": "40.761 -111.891"
    }
}